ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Medicenna Therapeutics Corporation (QB)

Medicenna Therapeutics Corporation (QB) (MDNAF)

1.82
0.42
(30.00%)
Closed April 28 4:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
1.82
Bid
1.82
Ask
1.86
Volume
577,695
1.493 Day's Range 1.92
0.158 52 Week Range 1.92
Market Cap
Previous Close
1.40
Open
1.493
Last Trade
50
@
1.825
Last Trade Time
Financial Volume
$ 1,021,532
VWAP
1.7683
Average Volume (3m)
137,733
Shares Outstanding
69,637,469
Dividend Yield
-
PE Ratio
-17.26
Earnings Per Share (EPS)
-0.14
Revenue
-
Net Profit
-10.05M

About Medicenna Therapeutics Corporation (QB)

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Toronto, Ontario, Can
Founded
1970
Medicenna Therapeutics Corporation (QB) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker MDNAF. The last closing price for Medicenna Therapeutics (QB) was $1.40. Over the last year, Medicenna Therapeutics (QB) shares have traded in a share price range of $ 0.158 to $ 1.92.

Medicenna Therapeutics (QB) currently has 69,637,469 shares outstanding. The market capitalization of Medicenna Therapeutics (QB) is $173.40 million. Medicenna Therapeutics (QB) has a price to earnings ratio (PE ratio) of -17.26.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.570145.61164893191.24991.921.0941811578271.32241143CS
40.44532.36363636361.3751.921.030561289271.33934284CS
121.512490.9090909090.3081.920.3081377331.01273263CS
261.6561009.756097560.1641.920.1581124020.7334773CS
521.6561009.756097560.1641.920.1581124020.7334773CS
1561.6561009.756097560.1641.920.1581124020.7334773CS
2601.2818238.1642512080.53825.320.158711821.74274036CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
BDRXBiodexa Pharmaceuticals PLC
$ 1.3254
(82.86%)
70.82M
IBRXImmunityBio Inc
$ 7.35
(43.84%)
40.28M
AGENAgenus Inc
$ 11.685
(40.78%)
3.37M
ULHUniversal Logistics Holdings Inc
$ 45.63
(38.74%)
484.22k
NIVFNewGenIvf Group Ltd
$ 1.77
(36.15%)
57.78M
MFImF International Ltd
$ 2.3153
(-77.82%)
21.23M
NWGLNature Wood Group Ltd
$ 5.05
(-70.03%)
2.48M
ICLKiClick Interactive Asia Group Ltd
$ 1.21
(-52.17%)
719.95k
NUWENewellis Inc
$ 0.1695
(-41.35%)
18.46M
SGBXSafe and Green Holdings Corporation
$ 0.1469
(-32.92%)
8.39M
PEGYPineapple Energy Inc
$ 0.065499
(26.20%)
325.57M
SQQQProShares UltraPro Short QQQ
$ 11.43
(-4.75%)
137.28M
INTCIntel Corporation
$ 31.88
(-9.20%)
119.84M
TSLATesla Inc
$ 168.29
(-1.11%)
109.84M
SOFISoFi Technologies Inc
$ 7.87
(3.69%)
88.63M

MDNAF Discussion

View Posts
2H2 2H2 4 days ago
MDNAF is a presenter at ASCO. Huge news!
πŸ‘οΈ0
2H2 2H2 3 weeks ago
Great presentation at ASCO
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
It is what they all say about stonks trading on Cromwell Coulson’s stonk market
πŸ‘οΈ0
2H2 2H2 2 months ago
Relishing soon. This will be 10x current value this year
πŸ‘οΈ0
Monksdream Monksdream 2 months ago
Delisted from Nasdaq
Gee, it sure is great to watch the price of a stock I bought at $400 a share advance to a 52=week high
πŸ‘οΈ0
2H2 2H2 2 months ago
Getting legs here. Train leaving.
πŸ‘οΈ0
axelvento axelvento 5 months ago
Cash runway extended through multiple data readouts and into Q1 of calendar 2025

MDNA11 is generally well tolerated and continues to demonstrate encouraging single-agent activity from Phase 1 portion of the ABILITY-1 Study including 100% and 70% reduction of target lesions in pancreatic and melanoma cancer patients, respectively

https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-second-quarter-fiscal-2024
πŸ‘οΈ0
Renee Renee 6 months ago
MDNA changed to MDNAF. Delisted from the Nasdaq to the OTC.

https://otce.finra.org/otce/dailyList?viewType=Additions
πŸ‘οΈ0
Monksdream Monksdream 7 months ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
MDNA new 52 week low
πŸ‘οΈ0
Monksdream Monksdream 8 months ago
MDNA NEW 52 week low
πŸ‘οΈ0
Investopotia Investopotia 2 years ago
Medicenna Therapeutics $MDNA highlighted in Midas Letter/BioPub interview: Top Stocks to Buy Now? 3 Biotech Stocks for your Watchlist
πŸ‘οΈ0
EagleD EagleD 3 years ago
Going much higher. Double digits in a few months
πŸ‘οΈ0
EagleD EagleD 3 years ago
Nice after hours action, Just made 20,000. Yadda Yadda Yadda.

Nobody is here listening to me. THis one is going to be a beast tho
πŸ‘οΈ0
EagleD EagleD 4 years ago
FDA meeting Tuesday. Seems like we'll know sometime in October the results
πŸ‘οΈ0
EagleD EagleD 4 years ago
This is my largest holding -- ever. Lots of value to be unveiled here in the coming months.
πŸ‘οΈ0
Renee Renee 4 years ago
MDNA moved from the OTC to the Nasdaq:

https://otce.finra.org/otce/dailyList?viewType=Deletions
πŸ‘οΈ0
tykundegex tykundegex 5 years ago
Just stumbled onto this co.. was doing some research. Great interim results in their Phase2b! Encouraging grants in the past, and prestigious medical centers for their trials. I may nibble to create a starting position here.

I can't find any webinars or conf call recordings that the company has given, do you know if any exist?
πŸ‘οΈ0
BioSpecialist BioSpecialist 7 years ago
Nice move yesterday ..

Small Phase 2b trial has huge chance to be successful because it was already successfull in prior studies so this stock like to be above $10 after phase 2 results in early Q1 . And that Management holding 15+ million shares of the 24.3 million shares outstanding makes me also optimistic .GL


MDNA55 is enrolling patients in a Phase 2b clinical trial for rGB at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGB, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4-ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment,


Medicenna Phase 2b trial using Brainlab technology
http://www.biotuesdays.com/briefs/2017/6/8/medicenna-phase-2b-trial-using-brainlab-technology

The current Phase 2b clinical trial plans to enroll 43 adult patients with rGB at leading brain cancer centers in the U.S.
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock